a New Front
in the War against Cancer
developing advanced therapies designed
to target and destroy the deadliest cancers
- melanoma, liver and breast - while
minimizing side effects
An Investigational Drug for Cancer
An Investigational Drug for Psoriasis and Atopic Dermatitis
Provectus presented at the Asia Biotech Invest Conference in Hong Kong on May 20, 2015 at 10:00 AM HKT.
A recent BioTuesday article discusses Provectus' novel approach of using physical chemistry and a different basis for the mechanism of action of its Rose Bengal based investigational anti-cancer agents, including PV-10, currently in phase 3 clinical testing.
Kate's Foundation created a news brief on last week's Modern Medicine/Dermatology Times article on treating metastatic melanoma with investigational drug PV-10.
An article appearing in Dermatology Times titled "Intralesional therapy for metastatic melanoma" discusses the "bystander" effect seen in clinical testing of intralesional PV-10 for melanoma and clinical evidence from studies at Moffitt Cancer Center that intralesional PV-10 induces a systemic immune response.
In support of Melanoma Awareness Month, an interview of Dr. Sanjiv Agarwala was aired on iHeart Radio 24/7 News on May 7, 2015.
Beginning May 4, 2015, an ad was aired on WAEB NewsRadio 790 in Allentown, PA informing the community that Provectus is seeking patients for the phase 3 trial of PV-10 for melanoma and that patients may now enrol at St. Luke's University Hospital and Health Network in Bethlehem, PA.
Audrey Adams recently interviewed Sanjiv Agarwala, MD on the syndicated radio program Talk With Audrey.
A DDN News article discusses the intralesional drug candidates, including PV-10, that are currently being investigated for advanced melanoma treatment.
Provectus will hold its quarterly business update conference call at 4 p.m. (EDT) May 7, 2015 to provide a business update on PV-10 and PH-10 to the investment community and answer questions from investors.
In recognition of National Melanoma Skin Cancer Prevention Month, Melanoma News Today reports on promising new strategies for the treatment of melanoma, including PV-10.
The Clinical News section of the April 27, 2015 edition of BioCentury included a clinical status update for Provectus reporting the initiation of a phase 3 trial of PV-10 for melanoma.
A Newswise article announces that Dr. Sanjiv Agarwala is available for media interview to discuss cutting-edge treatments that represent the recent surge in research aimed at battling late stage melanoma.
A BioPharm Insight article reports on Provectus efforts to partner with companies having PD1 or PDL1 inhibitor agents in late-stage development, noting the recently approved joint patent with Pfizer covering the use of PV-10 in combination with systemic inhibitors of immune system regulation.
Dermwire covers news that Provectus an Pfizer have received allowance from the FDA for a jointly held patent protecting the use of PV-10 in combination with systemic inhibitors of immune system regulation.
An audio recording of Provectus' panel discussion on Thursday, April 9, 2015 at The Harvard Club of New York City is now available.
Dermwire covers news that Provectus has opened enrollment of patients for its phase 3 international FDA comparative clinical trial of PV-10 for melanoma.
Slides are now available from Provectus' presentation at ChinaBio Partnering Forum 2015.
Webcast and slides from Provectus' presentation at Growth Capital Expo 2015 are available for download.
An article appearing on Healio discusses the Phase 3 trial of PV-10 for locally advanced cutaneous melanoma that is soon to begin recruiting, and includes quotes from Dr. Sanjiv Agarwala regarding trial design.
A poster presentation at the HemOnc Today Melanoma and Cutaneous Malignancies Annual Meeting presents an overview of study PV-10-MM-31, Provectus' Phase 3 trial of PV-10 for locally advanced cutaneous melanoma.
Provectus today announced that it had extended for an additional 60 days its Memorandum of Understanding with with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI"), the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK"), the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group.
Provectus announced today that the abstract titled, "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver," to be presented at the European Society for Medical Oncology's 17th World Congress on Gastrointestinal Cancer, is scheduled for Thursday, July 2, 2015 from 10:30 to 11:00 a.m. and 4:55 to 5:25 p.m. local time. Sanjiv S. Agarwala, MD, of St. Luke's University Hospital and Health Network, Bethlehem, PA, will be the presenter.
Provectus provided the market with a business update in its quarterly investor conference call held on Thursday, May 7, 2015, that addresses several matters in conjunction with the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.
Provectus today announced its results of operations and financial condition for the first quarter ended March 31, 2015.
Provectus announced that it has received notification of allowance from the European Patent Office for its patent application protecting the synthetic process used to produce the small molecule Rose Bengal, the active pharmaceutical ingredient (API) in PV-10, the 'Company's lead oncology drug candidate. At the same time, the Japanese Patent Office has issued a patent for the same intellectual property.
Provectus announced today that the European Society for Medical Oncology (ESMO) has accepted the Company's abstract, "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver," for poster presentation at the ESMO 17th World Congress on Gastrointestinal Cancer.
Provectus announced today that it will hold its quarterly business update conference call at 4 pm Eastern Daylight Time, on Thursday, May 7, 2015.
Provectus announced today that it will present at the Asia Biotech Invest 2015 Conference, on Wednesday, May 20, 2015, at 10 am local time.
Provectus announced today that it has received from the US Patent and Trademark Office a Notice of Allowance for a joint patent application made with Pfizer, Inc. The patent will protect use of PV-10 in combination with certain other types of drugs in the treatment of melanoma and cancers of the liver.
Provectus enters phase 3 and has opened enrollment of patients for its phase 3 international FDA comparative clinical trial of PV-10 for melanoma.
Provectus announced today that it will present at the 7th Annual International Partnering Conference, ChinaBio Partnering Forum 2015, in Shanghai, China.
Provectus announced today that Dr. Sanjiv Agarwala will present data on PV-10, the Company's novel investigational drug for cancer, at the HemOnc Today Melanoma and Cutaneous Malignancies Annual Meeting on Friday, April 10, 2015 at the Sheraton New York Times Square Hotel.
Provectus announced today that it will present at the Growth Capital Expo at 1 pm PDT on Monday, April 13, 2015. The Expo is being held at Caesars Palace, April 12-14, 2015.
Provectus announced today that it will present at the 12th Annual BIO Asia International Conference, taking place on March 24th and 25th at the Grand Hyatt in Tokyo, Japan.
Provectus announced today that the amended protocol for its phase 3 study of PV-10 as a treatment for melanoma is now available at: http://clinicaltrials.gov/ct2/show/study/NCT02288897. The Company does not require additional review from the U.S. Food and Drug Administration(the "FDA") to start the phase 3 study, and has begun the process of gaining approval from the Institutional Review Board (IRB) of each individual site for the amended protocol.
Provectus today provides the market with a business update that addresses several matters.
Provectus announced today that it has received U.S. Patent No. 8,974,363 from the United States Patent and Trademark Office (USPTO).
Provectus today announced its results of operations and financial condition for the fourth quarter and year ended December 31, 2014.
Provectus announced today that it will hold its year-end quarterly business update conference call at 4 pm Eastern Daylight Time, on Thursday, March 12, 2015.
Provectus announced today that it will present at the 8th Annual European Life Science CEO Forum & Exhibition. Peter Culpepper, CFO and COO, will present on March 3, 2015, at 3:15 pm local time.
(c) 2002-2015 Provectus Biopharmaceuticals, Inc.
All rights reserved.
Artwork designed by Tracy E. Miller.